Skip to Content

Set Your Location to See Relevant Information

Setting your location helps us to show you nearby providers and locations based on your healthcare needs.

MyBillingsClinic

SHARE

Clinical Trials Details

T790 M Resistance Expanded Access Trial

An Expanded Access Protocol of Oral Rociletinib (CO-1686) as Epidermal Growth Factor Receptor (EGFR) -Directed Therapy for Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) with T790M Resistance Mutation

Objective

To provide access to rociletinib for patients with advanced or metastatic EGFR-mutant NSCLC who have been treated previously with EGFR-directed therapy and have evidence of a T790M mutation (T790M+).

 

Must have documented evidence of one or more activating EGFR mutations (excluding the exon 20 insertion mutation) and the T790M resistance mutation.

Prior treatment with an approved or experimental EGFR-directed therapy.

Requirement of therapy due to disease progression confirmed by radiologic and/or clinical assessment and/or intolerance to prior EGFR-directed therapy.

 

 

IRB Protocol Number
CO-1686-031
Contact
Judy Miller, RN CCRP at 406-435-7482
or jmiller4@billingsclinic.org